EUVIMEDEuropean Health Evidence
Uhr Sources10/10 Journal Tree
Easy Demo

European Health Evidence

The European alternative to PubMed

EUVIMED is the European alternative to PubMed: a central, multilingual research platform for medicine, nursing, life sciences and healthcare. It brings together international and European literature sources, study registries, open-access full texts, citations and retraction notices in one search. Unlike pure bibliographic databases, EUVIMED supports the entire research process – from discovery and appraisal with LIVIA and CLARA to traceable evidence synthesis. European in focus, transparent, interoperable and designed for science and healthcare.

EuropeanMultilingualInteroperableTraceable

EUVIMED BETA

EUVIMED is currently in beta

EUVIMED is under continuous development. Features, data coverage and presentation may change or be temporarily incomplete.

Results are beta

Search results, classifications, summaries and AI-assisted assessments may be incomplete, delayed or incorrect.

Check original sources

Do not use EUVIMED results without verification for diagnosis, treatment or other clinical decisions. Always consult the original source and applicable guidelines.

Errors and feedback help us improve EUVIMED: info@euvimed.com

Lokaler Crossref-Datenbestand · journal-article

Early clinical and laboratory indicators for differentiating infectious from autoimmune encephalitis in pediatric patients: A single‐center retrospective cohort study

Ruth Vela Sosa, Audrey Uong, Alvaro Coronado‐Muñoz

Journal of Hospital Medicine · 2026

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Abstract Background Pediatric encephalitis is associated with significant morbidity. Early recognition of autoimmune encephalitis (AE) is critical for timely immunotherapy and improved outcomes. Objectives To externally validate a previously published adult encephalitis prediction model in a pediatric cohort and identify predictors of pediatric AE. Methods This retrospective single‐center study included children 90 days to 21 years with encephalitis between January 2016 and September 2025. Clinical and laboratory data were extracted using electronic health record. External validation used published coefficients. Discrimination and calibration were assessed using receiver operating characteristic analysis and slope estimation. An exploratory multivariable logistic regression model was constructed. Results One hundred and twenty‐six patients were included (92 autoimmune, 34 infectious). Patients with AE were significantly older (median age 14 vs. 5.5 years, p < .001). Infectious encephalitis was associated with higher serum white blood cell (WBC) (10.8 vs. 8.0 k/µL; p = .033) and cerebrospinal fluid (CSF) WBC (11 vs. 1 cells/µL; p < .001). The model showed acceptable discrimination (area under the receiver operating characteristic curve 0.774; 95% confidence interval [CI] 0.635–0.913) and calibration (slope 1.14; 95% CI 0.45–1.83). In our exploratory model ( n = 80), CSF protein ≥30 mg/dL, was associated with lower odds of AE (odds ratio [OR] 0.24; 95% CI 0.07–0.80; p = .021), while increasing age was associated with higher odds (OR 1.13/year; 95% CI 1.01–1.26; p = .031). Conclusions Predictors derived from an adult encephalitis model may retain some relevance in pediatrics despite physiologic differences. Specific pediatric predictors of AE included CSF protein

Bibliografischer Nachweis

Publikationsdaten

Autor:innen
Ruth Vela Sosa, Audrey Uong, Alvaro Coronado‐Muñoz
Quelle
Journal of Hospital Medicine
Publikation
2026-01-01
Band / Ausgabe
Nicht angegeben
Seiten
Nicht angegeben
ISSN / ISBN
1553-5592, 1553-5606
Zitationen
0 laut Crossref
Referenzen
0 hinterlegt

Zitieren

Zitierfähiger Nachweis

Ruth Vela Sosa, Audrey Uong, Alvaro Coronado‐Muñoz (2026). Early clinical and laboratory indicators for differentiating infectious from autoimmune encephalitis in pediatric patients: A single‐center retrospective cohort study. Journal of Hospital Medicine. https://doi.org/10.1002/jhm.70443
RIS BibTeX CSL-JSON

Kontext

Themen, Förderung und Nutzung

Lizenzhinweise: Lizenz 1 · Lizenz 2